Oxford BioMedica

Last updated: 13.02.2014

Address: Medawar Centre, Robert Robinson Avenue, The Oxford Science Park, Oxford, OX4 4GA,United Kingdom

Tel: +44 (0) 1865 783 000

Web: http://www.oxfordbiomedica.co.uk/

Company description

Oxford BioMedica has established a platform of technologies in gene delivery and immunotherapy, protected by an extensive intellectual property estate. Through in-house and collaborative development, the Company has a broad pipeline of gene-based product candidates for the treatment of age-related or inherited neurodegenerative and ocular diseases. In addition, Oxford BioMedica and its collaborators are developing novel targeted therapies and therapeutic vaccines to treat multiple types of cancer.

Products and services

Oxford BioMedica’s two lead programmes are a gene therapy for Parkinson’s disease (ProSavin®) in Phase I/II development and a therapeutic cancer vaccine (TroVax®) in Phase II development.

The other products include RetinoStat®, StarGen™, UshStat™, EncorStat™, MoNuDin®, Hi-8® MEL, MetXia®, EndoAngio-GT and Targeted Antibody Therapy.


We use cookies to ensure that we give you the best experience on our site. For more info

See our Cookie Privacy Policy Here